Effects of increasing age, dosage, and duration of PTH treatment on BMD increase - A meta-analysis

Calcified Tissue International

Volumn 90, Issue 3, 2012, Pages 165-173

  Schwarz, Peter ^a,b   Jorgensen, Niklas Rye ^a   Mosekilde, Leif ^c   Vestergaard, Peter ^c  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bone mineral density; Fracture; Meta analysis; Parathyroid hormone

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO;

AGING; ARTICLE; BONE DENSITY; DRUG EFFECT; FRACTURE; HIP; HORMONE SUBSTITUTION; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SPINE; SPINE FRACTURE; SYSTEMATIC REVIEW; TREATMENT DURATION; DOSE RESPONSE; FEMALE; MALE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOGRAPHY; REVIEW;

AGING; BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PARATHYROID HORMONE; SPINE;

EID: 84868322654     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-011-9564-3     Document Type: Article

References (36)

1. Johnell O (1997) The socioeconomic burden of fractures: today and in the 21st century. Am J Med 103: 20S-25S
2. Kannus P, Niemi S, Parkkari J, Palvanen M, Vuori I., Järvinen M (1999) Hip fractures in Finland between 1970 and 1997 and predictions for the future. Lancet 353: 802-805
3. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi M.L., Albanese C., Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster J.Y. (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87: 2060-2066
4. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski J.E., Spector TD, Cannata J, Balogh A, Lemmel E.M., Pors-Nielsen S, Rizzoli R, Genant H.K., Reginster J.Y. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with post-menopausal osteoporosis. N Engl J Med 350: 459-468
5. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J.Y., Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak B.H. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441
6. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman J.M., Clancy AD, Gaich G.A. (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18: 9-17
7. Reginster JY, Meunier P.J. (2003) Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporosis Int 14: 56-65
8. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C., Devogelaer JP, Curiel MD, Sawicki A, Goemaere S., Sorensen OH, Felsenberg D, Meunier P.J. (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmeno-pausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90: 2816-2822
9. Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L., Adachi JD, Shea B, Tugwell P, Wells G., Osteoporosis Research Advisory Group (ORAG) (2001) A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis Int 12: 140-151
10. Cranney A, Welch V, Adachi JD, Guyatt G, Krolicki N, Griffith L., Shea B, Tugwell P, Wells G. (2001) Etidronate for treating and preventing postmenopausal osteoporosis. Cochrane Database Syst Rev 2001; (4):CD003376
11. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N., Robinson V, Black D, Adachi J., Shea B, Tugwell P, Guyatt G., Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23: 508-516
12. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N., Papaioannou A, Robinson V, Shea B., Wells G, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23: 517-523
13. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B., Adachi J, Wells G, Shea B., Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23: 524-528
14. Torgerson DJ, Bell-Syer SEM (2001) Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trials. JAMA 285: 2891-2897
15. Torgerson DJ, Bell-Syer SEM (2001) Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2: 7-10
16. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B., Shea B, Wells G, Adachi J., Waldegger L, Guyatt G, Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 23: 540-551
17. Cummings SR, San Martin J, McClung MR, Siris E.S., Eastell R., Reid IR, Delmas P, Zoog HB, Austin M, Wang A., Kutilek S, Adami S, Zanchetta J., Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756-765
18. Maraldo M, McMurdor MTF, Vestergaard P, Schwarz P. (2010) Evidence of effect of anti-resorptive medicine in the elderly and old. Eur Geriatr Med 1: 279-292
19. Schwarz P, Jørgensen NR, Mosekilde L, Vestergaard P (2011) The evidence for efficacy of osteoporosis treatment in men - a systematic review and meta-analysis of anti-resorptive and anabolic treatment in men. J Osteoporos 2011: 259818
20. Greenspan SL, Bone HG, Marriott TB et al (2005) Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): results from the TOP Study. J Bone Miner Res 20: S56
21. Vestergaard P, Jørgensen NR, Mosekilde L, Schwarz P (2007) Effects of parathyroid hormone on bone mineral density and fracture risk - a metaanalysis. Osteoporosis Int 18: 45-57
22. Vestergaard P, Mollerup CL, Frøkjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. (2000) Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 321: 598-602
23. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L., Shen V, Dempster D, Cosman F. (1997) Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350: 550-555
24. Böhning D (2000) Computer-assisted Analysis of Mixtures and Applications: Meta-analysis, Disease Mapping and Others. Chapman & Hall/CRC Press, Boca Raton
25. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud C.D. (1998) Parathyroid hormone treatment can reverse cortico-steroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102: 1627-1633
26. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller P.D., Peretz A., Dore RK, Correa-Rotter R, Papaioannou A, Cumming D.C., Hodsman A.B. (2002) A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87: 4528-4535
27. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S., Shen V. (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of boen mass after parathyroid hormone withdrawal. J Bone Miner Res 16: 925-931
28. Cosman F, Nieves J, Zion M, Woelfert L, Luckey M., Lindsay R. (2005) Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353: 566-575
29. Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein M.D., Neer R.M. (1998) Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34). JAMA 280: 1067-1073
30. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer R.M. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216-1226
31. Finkelstein JS, Arnold A.L. (1999) Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab 84: 1214-1219
32. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian J.P. (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85: 3069-3076
33. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F., Omizo M, Donley DW, Dalsky G.P., Eriksen E.F. (2005) Opposite bone remodeling effects of Teriparatide and alendronate in increasing bone mass. Arch Intern Med 165: 1762-1768
34. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang T.F., Garnero P., Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmeno-pausal osteoporosis. N Engl J Med 349: 1207-1215
35. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T., Lang TF, McGowan JA, Rosen CJ, PaTH Study Investigators (2005) One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353: 555-565
36. Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe A.J., Lindsay R. (2003) Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in post-menopausal osteoporosis. J Clin Endocrinol Metab 88: 5212-5220